Commercial products

YUTREPIA™ (treprostinil) inhalation powder

YUTREPIA is an FDA-approved, inhaled dry-powder formulation of treprostinil indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Delivered through a convenient, low-resistance, palm-sized device, YUTREPIA was designed using Liquidia’s PRINT® technology. PRINT enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation.

EXPLORE YUTREPIA (TREPROSTINIL) INHALATION POWDER


See Prescribing Information

Report an Adverse Event 

To report SUSPECTED ADVERSE REACTIONS, contact Liquidia Technologies, Inc. at 1-888-393-LQDA (5732) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

YUTREPIA PRINT particles

  • 1.3 μm in size
  • Precisely engineered particles
  • Trefoil shape

Treprostinil Injection

Liquidia promotes the appropriate use of Sandoz® Treprostinil Injection in the United States in conjunction with its commercial partner, Sandoz, Inc. (Sandoz), which holds the Abbreviated New Drug Application (ANDA) with the FDA.

Treprostinil Injection is a fully substitutable AP-rated generic formulation of Remodulin® (treprostinil) Injection. Treprostinil Injection is therapeutically equivalent to Remodulin.

Remodulin® is a registered trademark of United Therapeutics Corporation.

Explore Treprostinil injection 


See Prescribing Information

Report an Adverse Event

Patient & family resources

As part of our work to support patients and their families, we are proud to connect patients with organizations that work to advance research and advocacy for people living with PAH and PH-ILD.

National Scleroderma Foundation
PHaware Global Association
Pulmonary Fibrosis Foundation
Pulmonary Hypertension Association
Team Phenomenal Hope